Sanofi-Aventis' Lantus Witnesses Positive Results

Published: 06-Jun-2009

A1C reductions, with many patients achieving the target A1C of less than 7%.

Sanofi-Aventis has come up with the results of a new study - Effects of 1, 2, or 3 prandial injections of insulin glulisine on glycemic control in type 2 diabetes patients on insulin glargine and oral drugs. The study evaluated patients adding prandial insulin Apidra administered before meals daily, already taking basal insulin, Lantus, with or without oral antidiabetic drugs(OADs).

The study was a multicenter, randomized, open-label, parallel group study in insulin naive patients. Lantus was started for a 14-week run-in period, after which time patients not at goal (A1C<7%) at week 0 were randomized to a 24-week intensified regimen of Lantus plus Apidra administered as above.

Mayer Davidson, M.D, Professor of Medicine, said: By combining basal insulin Lantus and Apidra mealtime insulin at one, two or three meals throughout the day, we observed A1C reductions with many patients achieving the target A1C of less than 7%.

Tell your friend about this article